MarketBeat | Real-Time Financial News and Analysis

Open Main Menu Open Sidebar

INDIVIOR PLC SPON ADR EA REPR 5 Company Profile (NASDAQ:INVVY)

Consensus Ratings for INDIVIOR PLC SPON ADR EA REPR 5 (NASDAQ:INVVY) (?)
Ratings Breakdown: No ratings tracked in the last 12 months.
Consensus Rating:N/A (Score: NaN)
Consensus Price Target: N/A

Analysts' Ratings History for INDIVIOR PLC SPON ADR EA REPR 5 (NASDAQ:INVVY)
Show:
No equities research coverage for this company has been tracked by MarketBeat.com

Earnings History for INDIVIOR PLC SPON ADR EA REPR 5 (NASDAQ:INVVY)
No earnings announcements for this company have been tracked by MarketBeat.com

Earnings Estimates for INDIVIOR PLC SPON ADR EA REPR 5 (NASDAQ:INVVY)
No earnings estimates for this company have been tracked by MarketBeat.com

Dividend History for INDIVIOR PLC SPON ADR EA REPR 5 (NASDAQ:INVVY)
No dividend announcements for this company have been tracked by MarketBeat.com

Insider Trading History for INDIVIOR PLC SPON ADR EA REPR 5 (NASDAQ:INVVY)
No insider trades for this company have been tracked by MarketBeat.com

Latest Headlines for INDIVIOR PLC SPON ADR EA REPR 5 (NASDAQ:INVVY)
DateHeadline
06/03/16 10:45 AMIndivior Welcomes Court Ruling on ANDA Litigation... - [at noodls] - 06.03.2016 | PDF Version Indivior PLC (LON:INDV) ('Indivior' or the 'Company') welcomes today's favourable ruling in the District Court of Delaware in the ANDA litigation against Actavis Laboratories Inc. ...
05/20/16 10:29 AMIndivior to Present New Data at ISPOR and ICOO that Assess Implications of Adherence, Healthcare Service Utilization and Costs in Opioid Use Disorder - [PR Newswire] - SLOUGH, England, May 20, 2016 /PRNewswire/ -- Indivior PLC (LON: INDV) will unveil new real-world data that assess relapse and Buprenorphine Medication-Assisted Treatment (B-MAT) adherence rates and healthcare ...
05/03/16 06:10 AMINDIVIOR PLC Q1 Financial Results Ahead of Plan. Full Year Guidance Confirmed.... - [at noodls] - 05.03.2016 | PDF Version Q1 Financial Highlights Net revenue at $258m (Q1 2015: $251m) grew 3%. Constant FX net revenue grew by 4%. Operating Profit of $101m (Q1 2015: $115m). Operating Margin of 39%. ...
04/28/16 08:47 AMResult of Phase 1 trial of RBP-6300 Buprenorphine Hemiadipate... - [at noodls] - 04.28.2016 | PDF Version RBP-6300, the oral swallowable capsule of Buprenorphine Hemiadipate for the treatment of opioid dependence, completed its Phase I clinical PK study (RB-EU-14-0001). The drug did ...
04/15/16 11:00 AMIndivior Presents Late-Breaking, Real-World Data Revealing Less than Half of Patients with Opioid Use Disorder Receive Medication-Assisted Treatment - [PR Newswire] - RICHMOND, Va., April 15, 2016 /PRNewswire/ -- Indivior Inc., a subsidiary of Indivior PLC (LON: INDV), presented new research from an analysis of more than 100,000 commercially insured patients indicating ...
04/08/16 07:37 AMIndivior Annual Report & Accounts 2015 and Annual General Meeting 2016... - [at noodls] - 04.08.2016 | PDF Version Indivior PLC ('Indivior' or the 'Company') Annual Report & Accounts 2015 and Annual General Meeting 2016 The Company has today posted or made available to shareholders the following ...
04/07/16 08:36 AMIndivior PLC (the “Company”) - Directorate Change... - [at noodls] - 04.07.2016 | PDF Version Indivior PLC announces that it intends to appoint Lizabeth Zlatkus as an independent Non-Executive Director with effect from September 1, 2016. Lizabeth will also be appointed ...
02/18/16 12:39 PMQuestor share tip: Sell Indivior after a wild first year on the stock market -
02/18/16 03:26 AMIndivior lifts profits but promises last dividend for foreseeable future -
12/09/15 06:50 AMIndivior PLC Research & Development Day in New York; Preliminary Financial Guidance FY 2016... - [at noodls] - 12.09.2015 | PDF Version Click here for Indivior R&D Day Webcast Event Click here for Indivior 2016 Financial Outlook Presentation Slough, UK, 9th December 2015 - Indivior PLC is today presenting its R&D ...
11/25/15 08:30 AMThe Zacks Analyst Blog Highlights: Gilead Sciences, Mylan, Indivior, OmniComm Systems and Air Methods -
11/24/15 11:21 AMIndivior Receives Complete Response Letter from FDA Not Approving Naloxone Nasal Spray New Drug Application for Opioid Overdose... - [at noodls] - 11.24.2015 | PDF Version Slough, UK, - Indivior Inc., a subsidiary of Indivior PLC (LON: INDV), today announced that it has received a Complete Response Letter from the U.S. Food and ...
11/24/15 10:47 AM5 Cheap Health Care Stocks that Promise Healthy Returns -
11/03/15 06:06 AMQ3 Results: Nine Month Financial Results Ahead of Plan – Full Year Guidance Raised... - [at noodls] - 11.03.2015 | PDF Version Nine Months Financial Highlights Net revenue at $766m (2014: $844m) declined 9% versus prior year with strong market growth offset by lower market share and higher rebates, in ...
10/21/15 09:07 PMIndivior Applauds Recent Momentum to Address Opioid Dependence and Overdose Epidemic... - [at noodls] - 10.21.2015 | PDF Version Slough, UK, 21 October 2015 - Indivior PLC (LON: INDV) is encouraged by recent efforts at the federal, state and local levels of government to expand access to treatment options ...
10/21/15 08:35 PMIndivior Applauds Recent Momentum to Address Opioid Dependence and Overdose Epidemic - [PR Newswire] - SLOUGH, England, Oct. 21, 2015 /PRNewswire/ -- Indivior PLC (INDV.L) is encouraged by recent efforts at the federal, state and local levels of government to expand access to treatment options as a means to help address the growing opioid dependence and overdose epidemic. The White House announcement of its plan to help reduce the rise in deaths from drug-related overdoses is another important step to confront this significant public health crisis. Efforts include providing greater access to treatment for opioid dependence, training to properly prescribe opioid medications and increasing availability of naloxone.
10/12/15 07:10 AMIndivior PLC Responds to Court's Decision on Motion to Amend - [PR Newswire] - SLOUGH, England, Oct. 12, 2015 /PRNewswire/ -- Indivior PLC (INDV.L) today announced that the U.S. District Court for the District of Delaware granted the Company's motion to amend its complaint to specifically refer to Teva Pharmaceuticals' Abbreviated New Drug Application (ANDA) No. 205299 to market a generic equivalent of two of the strengths of SUBOXONE® (buprenorphine and naloxone) Sublingual Film (CIII) in the United States. Since August 2013, Indivior has received Paragraph IV certifications from six companies that filed ANDAs seeking FDA approval to market a generic equivalent of SUBOXONE Film. Teva provided two Paragraph IV notices for ANDA submissions Nos.
10/12/15 01:49 AMIndivior PLC Responds to Court’s Decision on Motion to Amend... - [at noodls] - FOR IMMEDIATE RELEASE INDIVIOR PLC RESPONDS TO COURT'S DECISION ON MOTION TO AMEND Slough, UK, 12 OCTOBER 2015 - Indivior PLC (LON: INDV) today announced that the U.S. District Court for the District of ...
10/05/15 09:13 AMIndivior PLC Announces Research & Development Day on December 9th in New York... - [at noodls] - 09.08.2015 | PDF Version Slough, UK, 8th September 2015 - Indivior PLC today confirms that its R&D Science Day will now take place on December 9th in New York. This replaces the provisional date in October. ...
10/05/15 09:13 AMParagraph IV Notice from Mylan Technologies Inc... - [at noodls] - 10.01.2015 | PDF Version FOR IMMEDIATE RELEASE INDIVIOR PLC On 24 September 2015, Indivior Inc. ('Indivior') received a Paragraph IV notice of certification letter ('PIV Notice') from Mylan Technologies ...
10/05/15 09:03 AMParagraph IV Notice from Sandoz Inc.... - [at noodls] - 10.05.2015 | PDF Version FOR IMMEDIATE RELEASE Paragraph IV Notice from Sandoz Inc. ... This is an abstract of the original noodl. To continue reading this document, click here for the original version....
09/04/15 08:46 AMLannett Company (LCI) Looks Good: Stock Gains 12.8% -
08/31/15 08:25 AMApricus Biosciences (APRI) Looks Good: Stock Gains 9.8% -
07/29/15 07:00 AMIndivior PLC Announces FDA Acceptance of Naloxone Nasal Spray New Drug Application With Priority Review - [PR Newswire] - SLOUGH, England, July 29, 2015 /PRNewswire/ -- Indivior PLC (LON: INDV) today announced that the New Drug Application (NDA) for naloxone nasal spray was accepted and received Priority Review by the U.S. ...
About INDIVIOR PLC SPON ADR EA REPR 5

INDIVIOR PLC SPON ADR EA REPR 5 logo

Industry, Sector and Symbol:
  • Sector: N/A
  • Industry: N/A
  • Sub-Industry: N/A
  • Exchange: NASDAQ
  • Symbol: INVVY
  • CUSIP:
Key Metrics:
  • Previous Close: $16.75
  • 50 Day Moving Average: $13.808
  • 200 Day Moving Average: $12.483
  • P/E Ratio: 10.931
  • P/E Growth: 0.000
  • Market Cap: $2.13B
  • Current Quarter EPS Consensus Estimate: $N/A EPS
Additional Links:
INDIVIOR PLC SPON ADR EA REPR 5 (NASDAQ:INVVY) Chart for Monday, June, 27, 2016


            As Featured by CNBC As Featured by The Wall Street Journal As Featured by MarketWatch As Featured by The Boston Globe As Featured by StockTwits As Featured by Seeking Alpha